Human immunoglobulin-G interactions

Checked as Human immunoglobulin G (intramuscular) in this data source.

Full monograph for Human immunoglobulin-G Check it against another medicine

Medicines

4 documented

Severity

Mechanism

Medicines documented to interact with Human immunoglobulin-G, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Fosphenytoin Sodiummatched approximately	Moderate	Others	A possible interaction between phenytoin and intravenous immunoglobulin (IVIG) was suspected in a case of fatal hypersensitivity myocarditis.	20 sources — open the full entry
Phenytoin Sodiummatched approximately	Moderate	Others	A possible interaction between phenytoin and intravenous immunoglobulin (IVIG) was suspected in a case of fatal hypersensitivity myocarditis.	20 sources — open the full entry
Rotavirus Vaccinematched approximately	Moderate	Others	INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.	24 sources — open the full entry
Yellow Fever Vaccinematched approximately	Moderate	Antagonism · Others	INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.2 documented mechanisms	48 sources — open the full entry

Conditions

Conditions in which Human immunoglobulin-G needs care, as documented in this source.

Thrombosis
Major
Thrombosis has been reported after treatment with immune globulin products. In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.
5 sources
1. "Product Information. Gamunex-C (immune globulin intravenous and subcutaneous)." Talecris Biotherapeutics (2011):
2. "Product Information. Gammaplex (immune globulin intravenous)." Bio Products Laboratory (2016):
3. "Product Information. Flebogamma (immune globulin intravenous)." Grifols USA LLC (2016):
4. "Product Information. Gamastan S/D (immune globulin intramuscular)." Grifols Therapeutics (2018):
5. "Product Information. Cuvitru (immune globulin subcutaneous)." Baxter Healthcare Corporation (2018):